Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medivir ABLTS:0GP7 61 Equity-to-Asset is 0.89 as of Jun. 2026, which is 11% above its 10-year median of 0.80. GuruFocus rates LTS:0GP7 with a GF Score™ of 61/100 and a GF Value™ of kr1.24 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,414 Biotechnology companies, Medivir AB ranks better than 80.69% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Medivir AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr295.80 Mil. Medivir AB's Total Assets for the quarter that ended in Jun. 2026 was kr331.20 Mil.
Therefore, Medivir AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.89.
The historical rank and industry rank for Medivir AB's Equity-to-Asset or its related term are showing as below:
LTS:0GP7'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5 Med: 0.8 Max: 0.9
Current: 0.89
During the past 13 years, the highest Equity to Asset Ratio of Medivir AB was 0.90. The lowest was 0.50. And the median was 0.80.
LTS:0GP7's Equity-to-Asset is ranked better than 80.69% of 1414
companies
in the Biotechnology industry
Industry Median: 0.68
vs LTS:0GP7: 0.89
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Medivir AB Equity-to-Asset Related Terms
Medivir AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Medivir AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0GP7 vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Medivir AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Medivir AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Medivir AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (LTS:0GP7) has a Equity-to-Asset of 0.89 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medivir AB and its competitors. This is 11% above median its historical median of 0.80. Over the past decade, Medivir AB's Equity-to-Asset has ranged from 0.50 to 0.90. According to the industry distribution chart, Medivir AB ranks #273 out of 1414 companies in the Biotechnology industry, placing it in the top 19.3%.
Is Medivir AB's Equity-to-Asset too high?
Medivir AB's current Equity-to-Asset of 0.89 is 11% above median its 10-year median of 0.80. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 0.90. The Biotechnology industry median Equity-to-Asset is 0.68. Medivir AB's value of 0.89 is 30.9% above this industry median. Based on the distribution chart, Medivir AB ranks #273 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medivir AB has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #273 out of 1414 companies for Equity-to-Asset. This places Medivir AB in the top 19% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Medivir AB's value of 0.89 is 30.9% above this benchmark. Historically, Medivir AB's own Equity-to-Asset has ranged from 0.50 to 0.90 over the past decade. While the company's 10-year median is 0.80 vs. the industry median of 0.68, Medivir AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medivir AB's current Equity-to-Asset of 0.89 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current Equity-to-Asset is 0.89, which is 11% above median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.24, compared to a current price of kr1.91 — trading 54% above its estimated fair value. The current Equity-to-Asset is 0.89, which is 11% above median its 10-year median of 0.80 and 30.9% above the Biotechnology industry median of 0.68. Medivir AB's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current Equity-to-Asset is 0.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (LTS:0GP7) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.91 is trading 54% above its estimated GF Value™ of kr1.24.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for LTS:0GP7:
Equity-to-Asset: 0.89 (11% above median its 10-year median of 0.80)
GF Value™: kr1.24 vs. price of kr1.91 (54% above fair value)
Industry Position: 30.9% above the Biotechnology median (#273 of 1414)
No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
61GF Score
Get the complete analysis for LTS:0GP7
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0GP7 has been successfully added to your 
